A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma
Open Access
- 15 July 2003
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 89 (2), 252-257
- https://doi.org/10.1038/sj.bjc.6601104
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- 1α,25‐Dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2Anz Journal of Surgery, 2001
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse modelDiseases of the Colon & Rectum, 1997
- 1α,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cellsin vitroClinical & Experimental Metastasis, 1994
- Estimates of the worldwide incidence of eighteen major cancers in 1985International Journal of Cancer, 1993
- 1,25-dihydroxyvitamin D3 (VD) receptor in human liver cancer cell lines and effect of VD on their proliferation.Kanzo, 1989
- Study on 1,25-dihydroxyvitamin D3 receptor in human liver cancer tissue.Kanzo, 1988
- Primary liver cancer. An eastern cooperative oncology group trialCancer, 1984
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961